CD274 and small cell lung carcinoma: Owing to various clinical trials advocating the use of anti-PD-L1 drugs in recurrent or ES-SCLC quoting significant difference in survival rates, the need for various predictive biomarkers arises, which might help in decision making regarding sustaining or quitting ICPI regimens.